Concepedia

Author

Georgina Speake

AstraZeneca (United Kingdom)

Also Known As

G SPEAKE, G. Speake, Georgina Speake

27

Publications

3.4K

Citations

12

H-Index

18

Concepts

All Affiliations

AstraZeneca (United Kingdom)University of Colorado Denver
GS

About

Georgina Speake is an author at AstraZeneca (United Kingdom) specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

33

2

Health Sciences

1

1

12

3

Cell Biology

1

1

21

4

Endocrinology

1

1

12

5

Obstetrics

1

1

12

Georgina Speake

×

8

Publications

2.6K

Citations

8

H-Index

YearCitations

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert,

Journal of Clinical Oncology

2011

1.6K

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra,

Journal of Clinical Oncology

2009

379

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal,

Journal of Clinical Oncology

2008

217

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Gillian Ellison, Emma Donald, Gael McWalter,

Journal of Experimental & Clinical Cancer Research

2010

152

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake,

Clinical Cancer Research

2010

118

Epidermal growth factor receptor immunohistochemistry

Fred R. Hirsch, Rafał Dziadziuszko, Nick Thatcher,

Cancer

2008

70

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For <i>In Vitro</i> Sensitivity to Gefitinib

D. Mark Hickinson, Gayle Marshall, Garry Beran,

Clinical and Translational Science

2009

21

Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Massimo Cristofanilli, Rachel Schiff, V. Valero,

Journal of Clinical Oncology

2009

12

Page 1